Literature DB >> 31149274

PREGABALIN TREATMENT OF PERIPHERAL NERVE DAMAGE IN A MURINE DIABETIC PERIPHERAL NEUROPATHY MODEL.

J Li1, X Chen1, X Lu1, C Zhang1, Q Shi1, L Feng1.   

Abstract

CONTEXT: Peripheral nerve lesions are a major complication of diabetes mellitus, the main clinical manifestations of which are numbness and pain involving the limbs.
OBJECTIVE: To determine the correlation between pregabalin treatment and diabetic peripheral neuropathic pain.
DESIGN: An experimental animal study in BALB/c mice. SUBJECTS AND METHODS: Diabetes models are established by injecting streptozotocin (STZ) into the abdominal cavities of mice. The correlation between the treatment effect, time, and dosage of pregabalin was determined. The effect of a type 1 organic cation transporter (Octn1) in the absorption of pregabalin was evaluated.
RESULTS: Pregabalin reduced tactile allodynia in diabetic mice. The best analgesic effect occurred when intestinal absorption was increased. Octn1 mediated pregabalin entry into intestinal epithelial cells, which influenced the absorption of pregabalin with a time-dependent fluctuation in the small intestine. Peripheral nerve damage caused by diabetes was dependent on time and dose of pregabalin, which was related to the regular expression of Octn1 in small intestinal epithelium.
CONCLUSIONS: Peripheral nerve damage caused by diabetes was dependent on time and dosage of pregabalin, which was related to the regular expression of Octn1 in small intestinal epithelium.

Entities:  

Keywords:  Octn1; curative effect; diabetes mellitus; peripheral lesion; pregabalin.

Year:  2018        PMID: 31149274      PMCID: PMC6525768          DOI: 10.4183/aeb.2018.294

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  22 in total

1.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 2.  Chronopharmacology and controlled drug release.

Authors:  Björn Lemmer
Journal:  Expert Opin Drug Deliv       Date:  2005-07       Impact factor: 6.648

3.  Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.

Authors:  Klaus Fink; David J Dooley; Wolfgang P Meder; Nirmala Suman-Chauhan; Sandra Duffy; Hans Clusmann; Manfred Göthert
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

4.  Discovery of the ergothioneine transporter.

Authors:  Dirk Gründemann; Stephanie Harlfinger; Stefan Golz; Andreas Geerts; Andreas Lazar; Reinhard Berkels; Norma Jung; Andrea Rubbert; Edgar Schömig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

Review 5.  Pregabalin: From molecule to medicine.

Authors:  Richard Kavoussi
Journal:  Eur Neuropsychopharmacol       Date:  2006-06-09       Impact factor: 4.600

6.  Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine.

Authors:  N Piyapolrungroj; C Li; H Bockbrader; G Liu; D Fleisher
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

7.  A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5).

Authors:  Anne-Marie Lamhonwah; Jennifer Skaug; Stephen W Scherer; Ingrid Tein
Journal:  Biochem Biophys Res Commun       Date:  2003-01-31       Impact factor: 3.575

Review 8.  The mammalian circadian timing system: from gene expression to physiology.

Authors:  Frédéric Gachon; Emi Nagoshi; Steven A Brown; Juergen Ripperger; Ueli Schibler
Journal:  Chromosoma       Date:  2004-08-03       Impact factor: 4.316

9.  Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection.

Authors:  T A C Vermeij; P M Edelbroek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-10-25       Impact factor: 3.205

10.  Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.

Authors:  David J Dooley; Cindy M Donovan; Wolfgang P Meder; Steven Z Whetzel
Journal:  Synapse       Date:  2002-09-01       Impact factor: 2.562

View more
  1 in total

1.  Lack of impact of OCTN1 gene polymorphisms on clinical outcomes of gabapentinoids in Pakistani patients with neuropathic pain.

Authors:  Abida Shaheen; Syed Mahboob Alam; Fahad Azam; Salman Ahmad Saleem; Moosa Khan; Syed Saud Hasan; Afrose Liaquat
Journal:  PLoS One       Date:  2022-05-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.